{"prompt": "['receiving experimental treatment with non-approved drugs at the time of enrolment are not eligible. Patients', 'receiving treatment with combinations of approved drugs are eligible, provided documentation and clearance', 'by the SCC.', 'Allocation within strata will be carried out using blocked randomisation in random blocks of 2, 4, or 6.', '4.6 Blinding', 'Due to the nature of the intervention being tested (exercise), investigators, research staff and patients cannot', \"be blinded to the patients' randomisation assignment. However, the laboratory processing patient samples\", 'and the statistician performing the a priori specified primary and secondary analyses will be blinded.', '5.0 CLINICAL PROCEDURES', 'Guidelines for Pre-Study Testing:', 'All laboratory tests that are specified in the eligibility criteria (absolute neutrophil count, platelet count,', 'creatinine, bilirubin, aspartate aminotransferase, PSA, serum testosterone) as well as blood-based markers', 'that are part of the Halabi score should be completed within 28 days before Cycle 0, Day 1 (see footnote', '#7). The CPET must be completed within 14 days of Cycle 0, Day 1. Participants are randomised after the', 'CPET.', 'Table 1. Summary of assessments. One cycle = 28 days. (Next page)', 'INTERVAL Protocol Version 4.0, 19 April 2018', '16']['Off-', 'Screening', 'On-Treatment Study Period\u00b9', 'Treatment', 'Table 1 Summary of', 'Cycle 0:', 'Follow-up', 'Assessments', 'Baseline2', 'Supervised Exercise', 'Transition', 'Self-managed exercise program', 'Period', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', 'Informed Consent', 'X', 'Randomisation', 'X4', 'Clinical History', 'Medical history', 'X', 'Tumour histology', 'X', 'Medication/Tx history', 'Body Measurements', 'Height', 'Weight, waist, hip circumference', 'Lab Studies', 'CBC w/diff, blood chemistries6', 'X6,8', 'X6,8', 'X6,8', 'Fasting Lipid Profile (LDL, HDL,', 'X', 'Triglycerides), fasting Glucose,', 'HbA1c', 'Efficacy', 'Overall survival status,', 'X9', 'X9', 'X9', 'Twice', 'Disease progression,', 'yearly9', 'Symptomatic-skeletal event9', 'X', 'X', 'X', 'Once', 'WHO analgesic scale', 'yearly9', 'CPET with ECG\u00b3', 'X10', 'X11', 'ARM A - Constant Load test10', 'X10', 'ARM A - 1-RM Strength test', 'X10', 'X11', 'X11', 'X11', 'X11', 'X11', 'ARM B - 1-RM Strength test', 'X10', 'X11', 'X11', 'X11', 'X11', '400 m walk test', 'X10', 'X11', 'X11', 'X11', 'X11', 'Safety', 'Medical Clearance(s)2', 'X', 'Vital signs13', 'X\u00b3', 'ECOG performance status', 'Bone pain at exercise visits', 'Assessed at each supervised exercise visit using VAS', 'Adverse events14', 'X', 'Concomitant medications15', 'X\u00b3', 'INTERVAL Protocol Version 4.0, 19 April 2018', '17']['Screening', 'On-Treatment Study Period\u00b9', 'Off-', 'Table 1 Summary of', 'Treatment', 'Assessments', 'Cycle 0:', 'Supervised Exercise', 'Transition', 'Self-managed exercise program', '(Continued)', 'Baseline2', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', 'Metabolic Research', 'Studies', 'Research blood (fasting)', 'X16', 'X17', 'X17', 'FFPE tumour specimens', 'Request18', 'Urine specimens', 'Patient Report Outcomes', 'Appx 5 Demographics &', 'X19', 'Health History Questionnaire', 'Appx 8 Exercise Screening', 'X', 'X21', 'Questionnaire', 'FACT-G, EPIC-26, FACIT-', 'X19', 'X21', 'Fatigue, EORTO QLQ-C30,', 'STAI, CES-D, PSQI, falls20', 'BPI-SF and EQ5D 20', 'X19', 'X21', 'Exercise questions modified', 'X19', 'from baseline, Modified', 'Godin exercise scale,', 'memory, exercise', 'motivation20', 'Diet20', 'X19', 'Cost of Participation', 'TABLE ABBREVIATIONS:', 'EMR: electronic medical record; CPET: Cardiopulmonary Exercise Test; ECG: Electrocardiogram; SOC: Standard of Care; ECOG: Eastern Cooperative Oncology', 'Group; PSA: Prostate Specific Antigen; EG: Exercise Group; FFPE: formalin-fixed paraffin-embedded; PFS: Progression-free survival; OS: overall survival; SSE:', 'symptomatic', 'skeletal-related events; BPI-SF: Brief-Pain Inventory Short Form; FACT-G: Functional Assessment of Cancer Therapy-General; FACIT: Functional', 'Assessment of Chronic Illness Therapy; EPIC-26: Expanded Prostate Cancer Index Composite Instrument, EQ5D: Euro-Quality of Life 5-dimension; STAI: State-', 'Trait Anxiety Inventory; CES-D: Centre for Epidemiologic Studies Depression', 'FOOTNOTES:', '1 The study period is comprised of cycles. Each cycle equals 28 days.', '2 Day 1 of the study period (baseline) is the same for each arm. It is defined as Day 1, Cycle 0 when the remainder of the baseline physical capacity and function tests are completed.', 'Men are randomised prior to this day. This day is also the first day of training in the Supervised Exercise/SE (intervention arm). The patient is to be told which arm they are randomised', 'into after Baseline testing is completed, which is at the end of Day 1, Cycle 0 testing - where \"next steps\" in the study are explained.', '3 Assessed at screening visit with exercise physiologist, trainer, etc., which must occur within 14 days prior to Day 1, Cycle 0. Concomitant medications are recorded by clinical', 'research coordinator in REDCap and exercise physiologist/trainer will review with patient at the CPET screening visit. The baseline anthropometric measurements do not need to be', 'INTERVAL Protocol Version 4.0, 19 April 2018', '18']\n\n###\n\n", "completion": "END"}